A multicentric prospective open trial on the quality of life and oxidative stress in patients affected by advanced head and neck cancer treated with a new benzoquinone-rich product derived from fermented wheat germ (Avemar)

Abstract

Background and aim

Anorexia/cachexia syndrome is frequently correlated with increased oxidative stress (OS). A fermented wheat-germ extract with a standardized benzoquinone content (brand name Avemar) has been shown to exert an intense antioxidant activity with no side effects. The aim of this study was to investigate the effects of Avemar in patients affected by head and neck cancer, correlating the variations with OS with the quality of life as assessed by the Spitzer’s index

Patients and methods

A cohort of 60 patients affected by head and neck tumours (stage IIIa, IIIb, IV) were enrolled in the study following an open-label protocol. The patients were assigned to two subgroups, A or B. Group A was treated with conventional oncological therapy alone, and group B was treated with Avemar in addition to standard therapy. After 2 months only 55 patients survived and could be evaluated (29 in the control group and 26 in the Avemar group). Each patient was checked for circulating concentrations of hydroperoxides using the FRAS III test

Results

The levels of OS significantly decreased after 2 months in the group receiving Avemar (group). The value of Spitzer’s index was significantly higher in group B, attesting to an improved quality of life

Conclusion

Although the specific active substance in Avemar has not yet been identified, the reduction in free oxygen radicals induced by it is correlated with a clinically significant improvement in the quality of life in patients with advanced cancer

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Nelson K, Walsh D (1991) Management of the anorexia/cachexia syndrome. Cancer Bull 43:403–406

    Google Scholar 

  2. 2.

    Brennan MR (1997) Uncomplicated starvation vs cancer cachexia. Cancer Res 37:2359–2364

    Google Scholar 

  3. 3.

    Bruera E (1992) Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49 [Suppl 2]:35–42

    Article  Google Scholar 

  4. 4.

    Mantovani G, Macciò A, Massa E, Madeddu C (2001) Managing cancer-related anorexia/cachexia. Drugs 61(4):499–514

    Article  CAS  Google Scholar 

  5. 5.

    Bruera E (1997) ABC of palliative care. Anorexia, cachexia and nutrition. BMJ 315:1219–1222

    CAS  Google Scholar 

  6. 6.

    Mantovani G, Madeddu C, Macciò A, Gramignano G et al (2004) Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 13:1651–1659

    CAS  Google Scholar 

  7. 7.

    Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 89:1681–1684

    Article  CAS  Google Scholar 

  8. 8.

    McLaughlin CL, Rogan GJ, Ton J (1992) Food intake and body temperature responses of rat to recombinant interleukin 1 beta and a tripeptide interleukin 1 beta antagonist. Physiol Behav 52:1155–1160

    Article  CAS  Google Scholar 

  9. 9.

    Malmberg KJ, Lenkei R, Petersson M et al (2002) A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res 8:1772–1778

    CAS  Google Scholar 

  10. 10.

    Bingisser RM, Tilbrook PA, Holt PG, Kees UR (1998) Macrophage-derived nitric oxide regulates T-cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160:5729–5734

    CAS  Google Scholar 

  11. 11.

    Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240

    Article  CAS  Google Scholar 

  12. 12.

    Sabitha KE, Shyamaladevi CS (1999) Oxidant and antioxidant activity changes in patients with oral cancer and treated with chemotherapy. Oral Oncol 35:273–277

    Article  CAS  Google Scholar 

  13. 13.

    Malmberg KJ, Lenkei R, Petersson M et al (2002) A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res 8:1772–1778

    CAS  Google Scholar 

  14. 14.

    Illmer C, Madlener S, Horvath Z et al (2005) Immunologic and biochemical effects of the fermented wheat germ extract Avemar. Exp Biol Med 230:144–149

    CAS  Google Scholar 

  15. 15.

    Sukkar SG, Rossi E (2004) Oxidative stress and nutritional prevention in autoimmune rheumatic diseases. Autoimmun Rev 3:199–206

    Article  CAS  Google Scholar 

  16. 16.

    Comìn-Anduix B, Boros LG, Marin S et al (2002) Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumour cells. J Biol Chem 277:46408–46414

    Article  CAS  Google Scholar 

  17. 17.

    Fajka-Boja R, Hidvégi M, Shoenfeld Y et al (2002) Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumour T and B cell lines. Int J Oncol 20:563–570

    CAS  Google Scholar 

  18. 18.

    Gritz ER, Carmack CL, de Moor C et al (1999) First year after head and neck cancer: quality of life. J Clin Oncol 17:352–362

    CAS  Google Scholar 

  19. 19.

    Gritz ER, Hoffman A (1996) Behavioral and psychosocial issues in head and neck cancer. In: Beumer J, Curtis T, Marunick M (eds) Maxillofacial rehabilitation: prosthodontic and surgical considerations. Ishiyaku Euromica, St. Louis, pp 1–14

    Google Scholar 

  20. 20.

    Gotay CC, Moore TD (1992) Assessing quality of life in head and neck cancer. Qual Life Res 1:5–17

    Article  CAS  Google Scholar 

  21. 21.

    Bjordal K, Kaasa S (1995) Psychological distress in head and neck cancer patients 7–11 years after curative treatment. Br J Cancer 71:592–597

    CAS  Google Scholar 

  22. 22.

    Cornelli U, Terranova R, Luca S et al (2001) Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 131:3208–3211

    CAS  Google Scholar 

  23. 23.

    Spitzer WO, Dobson AJ, Hall J (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585–597

    Article  CAS  Google Scholar 

  24. 24.

    Michael M, Tannock IF (1998) Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ 158:1727–1734

    CAS  Google Scholar 

  25. 25.

    Filiberti A (1990) Strumenti di validazione multidimensionale della qualita della vita. In: Tamburini M (ed) La valutazione della qualita della vita in oncologia. Masson, Milan

    Google Scholar 

  26. 26.

    Sloan JA, Loprinzi CL, Kuross SA et al (1998) Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 16:3662–3673

    CAS  Google Scholar 

  27. 27.

    Jakab F, Shoenfeld Y, Balogh A et al (2003) A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer 89:465–469

    Article  CAS  Google Scholar 

  28. 28.

    Mantovani G, Maccio A, Madeddu C et al (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 98:84–91

    Article  CAS  Google Scholar 

  29. 29.

    Mantovani G, Maccio A, Madeddu C et al (2003) The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokine in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 37:213–223

    Article  CAS  Google Scholar 

  30. 30.

    Mantovani G, Maccio A, Melis G et al (2000) Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants α-lipoic acid and Nacetyl cysteine. Int J Cancer 86:842–847

    Article  CAS  Google Scholar 

  31. 31.

    Capuron L, Dantzer R (2003) Cytokines and depression: the need for a new paradigm. Brain Behav Immun 17 [Suppl 1]:S119–S124

    Article  CAS  Google Scholar 

  32. 32.

    Fajka-Boja R, Hidvegi M, Shoenfeld Y et al (2001) Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Oncol 20:563–570

    Google Scholar 

  33. 33.

    Griffioen AW, Damen CA, Martinotti S et al (1996) Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 56:1111–1117

    CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Samir G. Sukkar.

About this article

Cite this article

Sukkar, S.G., Cella, F., Rovera, G.M. et al. A multicentric prospective open trial on the quality of life and oxidative stress in patients affected by advanced head and neck cancer treated with a new benzoquinone-rich product derived from fermented wheat germ (Avemar). Mediterr J Nutr Metab 1, 37 (2008). https://doi.org/10.1007/s12349-008-0008-4

Download citation

Keywords

  • Fermented wheat germ extract
  • Head and neck cancer
  • Quality of life
  • Oxidative stress
  • D-ROMs test